Literature DB >> 2455352

Determining successful pain clinic treatment through validation of cost effectiveness.

J W Simmons1, W S Avant, J Demski, D Parisher.   

Abstract

Initially, the Center for Pain Control designed and implemented multiple measures to indicate treatment efficacy in an outpatient setting. Decreased use of medical care at 1 year after treatment was one of five measures used. Economic concerns, both in the health and the insurance industries, mandated greater emphasis on cost effectiveness at a primary success determinate. Cost effectiveness was measured through broad diagnostic categories: lumbar pain with or without radiculopathy, cervical pain with and without radiculopathy, and a combination of lumbar and cervical pain. Cost for surgical treatment was determined using community-based charges. This cost was compared to actual cost incurred by outpatient pain treatment together with 6 months aftercare. Significant savings is indicated by the above cost comparison.

Entities:  

Mesh:

Year:  1988        PMID: 2455352     DOI: 10.1097/00007632-198803000-00020

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  3 in total

1.  Aging baby boomers and the rising cost of chronic back pain: secular trend analysis of longitudinal Medical Expenditures Panel Survey data for years 2000 to 2007.

Authors:  Monica Smith; Matthew A Davis; Miron Stano; James M Whedon
Journal:  J Manipulative Physiol Ther       Date:  2013-01       Impact factor: 1.437

Review 2.  Interventional pain management for spinal disorders: a review of injection techniques.

Authors:  Mathias Wewalka
Journal:  Wien Med Wochenschr       Date:  2015-12-22

3.  Pain relief as a primary treatment goal: at what point does functioning and well-being become more important? A case study of an adolescent with debilitating chronic pain.

Authors:  Andrew S Tseng; Karen Weiss; Tracy Harrison; Daniel Hansen; Barbara Bruce
Journal:  Pain Res Manag       Date:  2014-04-07       Impact factor: 3.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.